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Introduction 16	  
 17	  
The use of indwelling devices is constantly increasing in modern medicine. Although they improve 18	  
patients’ care, it is recognised that their use is associated with the risk of infection. Device-related 19	  
infections represent a significant part of hospital-acquired infections and are due to device 20	  
contamination by microorganisms subsequently forming biofilms. These biofilms can be defined as 21	  
sessile communities encased in a self-produced matrix that protects them from external insults 22	  
including the host immune system and antimicrobial agents. Historically the first description of the 23	  
involvement of biofilms in a device-related infection was provided in 1982 by the observation of a 24	  
pacemaker colonised by Staphylococcus aureus [1]. Since then, formation of biofilms has been 25	  
described in all indwelling devices and is especially problematic in intensive care units (ICU) where 26	  
intravascular (including intracardiac) devices are extensively used. Among them, intravascular 27	  
catheters are used for different purposes in ICU including infusion, haemodialysis, parenteral nutrition, 28	  
hemodynamic monitoring or support such as during extracorporeal membrane oxygenation (ECMO) or 29	  
extracorporeal life support (ECLS). In part because of their repeated manipulation, the use of such 30	  
devices is associated with infection incidence densities ranging from 0.8 to 3.7 episodes per 1000 31	  
catheter-days, depending on ICU units [2]. Main microorganisms responsible for intravascular catheter 32	  
colonisation and subsequent infections depend on local epidemiology and type of ICU but mostly 33	  
include Staphylococcus spp, Gram-negative rods and yeasts. Most of the time, clinical symptoms of 34	  
intravascular catheter-related infections are unspecific, such as fever, chills or hypotension, and local 35	  
cutaneous signs such as redness or pain are seen in ~20% of the cases. 36	  
Here we will describe the different steps of bacterial biofilm formation on intravascular catheters and 37	  
strategies that can be developed to avoid or reduce their clinical consequences (Figure 1). Such a 38	  
physiopathologic scheme can also be applied to the formation of biofilm on other intravascular devices 39	  
such as cardiac prosthetic valves or pacemakers. 40	  
 41	  
Targeting early steps of colonisation  42	  
While initial contamination of intravascular catheters can occur through bacterial translocation from the 43	  
gut (typically in critically ill and oncology patients) or bloodstream infection (BSI) from another 44	  
infectious source (Figure 1A), the main route of contamination is the patient’s skin bacterial flora or 45	  
healthcare workers’ hand manipulating the catheter hub (Figure 1B and C, respectively). In this case, 46	  
contamination occurs mainly because of suboptimal aseptic measures and can lead to intra- or extra-47	  
luminal colonisation [3]. 	  48	  
Initial events of adhesion on abiotic surfaces such as intravascular catheters that will further lead to 49	  
colonisation are dependent on electrostatic interactions between bacteria and surfaces as well as 50	  
more specific interactions between bacterial surface appendages and host proteins that can rapidly 51	  
cover the implanted material (Figure 1D). These interactions are mediated through different types of 52	  
adhesins both in Gram-positive and Gram-negative bacteria such as flagella, homo- or hetero-53	  
polymeric fimbriae and large adhesins [4]. In Gram-negative bacteria, many of these biofilm-promoting 54	  
factors are activated by cyclic-di-GMP (c-di-GMP), an allosteric activator controlling free-swimming to 55	  
sessile lifestyle transition [5]. 56	  
The best prevention approach comes with hand hygiene and skin antisepsis for catheter insertion and 57	  
handling. Skin disinfection with chlorhexidine-alcohol has been proven to be the more active [6]. If 58	  
incidence of catheter-related infections is still high, other prophylactic strategies can be proposed 59	  
including chlorhexidine-impregnated sponges or microbiocides-impregnated catheters such as those 60	  
containing minocycline-rifampin [7]. While not in clinic yet, devices coated with natural or synthetic 61	  
antimicrobial peptides might provide in the future novel preventive solutions [8]. In the setting of ICU, 62	  
as catheters are continuously used, preventive lock therapies are of limited help. The principle of such 63	  
locks is to inject a small volume of highly concentrated antibiotics in the catheter lumen in order to 64	  
prevent or eradicate biofilm. One trial demonstrated that a short-course ethanol lock did not prevent 65	  
dialysis catheter-related infections [9]. Furthermore, the use of such ethanol locks may be associated 66	  
with catheter clotting and should therefore be carefully used. An alternative to biocidal treatment might 67	  
be translated in the future into the clinic by the use of anti-adhesive molecules avoiding initial 68	  
attachment such as coating of catheters with polymers like poly-ethylene-glycols or polysaccharides 69	  
(methyl-cellulose [10], ulvans) [11], or by interfering with the transition from free-swimming to sessile 70	  
lifestyle using c-di-GMP inhibitors (for example [12]). 71	  
 72	  
Targeting mature biofilms 73	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After initial attachment, maturation of biofilm essentially relies on communication between bacteria 74	  
through “quorum-sensing” (QS) molecules and the production of the biofilm matrix. The latter is 75	  
composed essentially of water and is structured by various macromolecules such as extra-cellular 76	  
DNA, polysaccharides and proteins (Figure 1E). This matrix not only governs biofilm architecture but 77	  
also provides protection against both the immune system and antimicrobial agents by reducing their 78	  
diffusion. At that stage, pieces of biofilms can shed in the bloodstream, leading to sepsis, septic 79	  
thrombophlebitis, or distant infections such as infective endocarditis or bone and joint infections 80	  
(Figure 1F). Growth of biofilms in the lumen of the catheter can also be responsible for catheter 81	  
clotting limiting its use. 82	  
The presence of the matrix within mature biofilms imposes gradients of nutrients, oxygen and waste 83	  
products leading to an important chemical heterogeneity [13] and thus promotes emergence, at a low 84	  
frequency, of phenotypic variants including the so-called persisters. Persisters, unlike most of the cells 85	  
composing the biofilms, can survive to extremely high levels of antimicrobial agents, and are thus 86	  
considered the main cause of biofilm antibiotic tolerance and of chronic and recurrent infections [14].  87	  
The diagnosis of catheter-related BSI (C-RBSI) is established when the same microorganism grows in 88	  
percutaneous blood cultures and on the catheter tip. It can also be made without removing the 89	  
catheter by means of the differential time to positivity or quantitative blood cultures techniques [15]. In 90	  
the last, blood samples from all catheters lumens must be cultured in order to increase sensitivity [16]. 91	  
Catheter withdrawal and systemic antimicrobials are the cornerstones of C-RBSI treatment. Antibiotic 92	  
lock therapy plus systemic antimicrobials is an effective and safe strategy to treat uncomplicated C-93	  
RBSI without catheter removal but should be restricted to long-term central venous catheters in stable 94	  
patients. As a consequence, it cannot be recommended routinely in ICU patients [17]. 95	  
In the future, however, some promising approaches might translate into the clinics. For example, 96	  
together with a systemic treatment, antibiotic adjuvants that destroy or destabilise the matrix and thus 97	  
weaken the biofilms such as enzymes (DispersinB, DNaseI) or cations chelators (EDTA [18]), or 98	  
molecules that directly target persister cells (sugars, ADEP4, antimicrobial peptides, etc) [19], could be 99	  
used as short-course catheter locks for catheter salvage. 100	  
 101	  
Conclusion and future challenges. 102	  
Intravascular catheter-related infections remain a major health issue especially in the ICU. Despite 103	  
promising approaches developed in research laboratories, in part because of molecule development 104	  
cost issues, limited relevance of some in vitro and in vivo animal models and the severity of patients, 105	  
the physicians in ICU still have very little options when facing such infections.  106	  
 107	  
When an ICU patient suffers from a C-RBSI, the safest option today remains removal of the colonised 108	  
catheter. Rapid improvements will probably come from preventive strategies firstly based on enhanced 109	  
hygiene. The next challenges for researchers will be to develop novel strategies to improve early 110	  
detection of biofilm formation before any symptoms are visible and to increase knowledge and 111	  
mitigation of polymicrobial biofilm infections that are now often detected in intravascular catheters and, 112	  
especially, intracardiac devices.  113	  114	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Figure 1. Schematic view of biofilm formation on the surface of a central venous catheter. 116	  
a Microbial contamination can come from a bloodstream infection (defining an hematogenous 117	  
contamination) but must most frequently originates from the patient’s skin (because of a lack of skin 118	  
antisepsis) (b) or from the catheter hub (c). These last two routes of contamination lead to 119	  
extraluminal and endoluminal colonisation, respectively. After contamination, reversible and 120	  
irreversible adhesion allow the microorganism to stick to the surface of the catheter (d). 121	  
Microorganisms multiply, form a microcolony and then evolve to mature biofilm (e) through matrix 122	  
production and quorum-sensing signals. f Lastly, dispersal of biofilm pieces or individual cells is 123	  
responsible for bloodstream infection and subsequent infection dissemination. 124	  
 125	  
126	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